Carnitine-acylcarnitine translocase deficiency: experience with four cases in Spain and review of the literature.

Autors de IIS La Fe
Autors aliens a IIS La Fe
- Martin-Hernandez, E
- Pena-Quintana, L
- Bueno, M
- Quijada-Fraile, P
- Molina-Marrero, S
- Perez, B
- Merinero, B
Grups d'Investigació
Abstract
BACKGROUND: Carnitine-acylcarnitine translocase (CACT) deficiency is a rare autosomal recessive disease in the mitochondrial transport of long-chain fatty acids. Despite early diagnosis and treatment, the disease still has a high mortality rate. METHODS: Clinical symptoms, long-term follow-up, and biochemical and molecular results of four cases are described and compared with the reviewed literature data of 55 cases. RESULTS: Two cases with neonatal onset, carrying in homozygosity the novel variant sequences p.Gly20Asp (c.59G>A) and p.Arg179Gly (c.536A>G), died during an intercurrent infectious process in the first year of life despite adequate dietetic treatment (frequent feeding, high-carbohydrate/low-fat diet, MCT, carnitine). The other two cases, one with infantile onset and the other diagnosed in the newborn period after a previous affected sibling, show excellent development at 4 and 16 years of age under treatment. The review shows that the most frequent presenting symptoms of CACT deficiency are hypoketotic hypoglycemia, hyperammonemia, hepatomegaly, cardiomyopathy and/or arrhythmia, and respiratory distress. The onset of symptoms is predominantly neonatal in 82% and infantile in 18%. The mortality rate is high (65%), most in the first year of life due to myocardiopathy or sudden death. Outcomes seem to correlate better with the absence of cardiac disease and with a higher long-chain fatty acid oxidation rate in cultured fibroblasts than with residual enzyme activity. CONCLUSION: Diagnosis before the occurrence of clinical symptoms by tandem MS-MS and very early therapeutic intervention together with good dietary compliance could lead to a better prognosis, especially in milder clinical cases.
Dades de la publicació
- ISSN/ISSNe:
- 2192-8304, 2192-8312
- Tipus:
- Article
- Pàgines:
- 11-20
- PubMed:
- 25614308
Jimd Reports SPRINGER-VERLAG BERLIN
Cites Rebudes en Web of Science: 29
Documents
- No hi ha documents
Filiacions
Projectes associats
ESTUDIO POSTAUTORIZACIÓN DE SEGURIDAD (EPAS) NO INTERVENCIONAL PARA EVALUAR LA SEGURIDAD A LARGO PLAZO DEL TRATAMIENTO CON ORFADIN EN LA TIROSINEMIA HEREDITARIA TIPO 1 (TH-1) EN LA PRÁCTICA CLÍNICA ESTÁNDAR.
Investigador Principal: ISIDRO VITORIA MIÑANA
SWE-NIT-2013-01 . 2014
ESTUDIO OBSERVACIONAL, AMBISPECTIVO DE HISTORIA NATURAL EN PACIENTES CON MUCOPOLISACARIDOSIS TIPO IIIA (MPS IIIA) O SÍNDROME DE SANFILIPPO TIPO A.
Investigador Principal: ISIDRO VITORIA MIÑANA
EST-SFA-2013-01 . 2014
ESTUDIO DE RESULTADOS DE HUNTER: REGISTRO OBSERVACIONAL, INTERNACIONAL Y MULTICÉNTRICO A LARGO PLAZO DE PACIENTES CON SÍNDROME DE HUNTER (MUCOPOLISACARIDOSIS DE TIPO II, MPS II).
Investigador Principal: ISIDRO VITORIA MIÑANA
SHI-IDU-2011-01 . 2014
PROTOCOLO DEL REGISTRO DE LA ENFERMEDAD DE GAUCHER.
Investigador Principal: ISIDRO VITORIA MIÑANA
GEN-GAU-2013-01 . 2018
PROTOCOLO DE VIGILANCIA DEL E-HOD/CYSTADANE.
Investigador Principal: JAIME DALMAU SERRA
ORP-CYS-2014-01